Inflammatory Myopathy
Conditions
Brief summary
The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.
Interventions
On the basis of the original foundational medication regimen, add Telitacicept 240mg administered via subcutaneous injection once a week for a total of 12 weeks.
Sponsors
Zhongming Qiu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Masking Description
Intervention model description
Model Description
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years and ≤ 70 years. * Patient has a confirmed diagnosis of inflammatory myopathy, meeting the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for idiopathic inflammatory myopathies. * Inadequate response or intolerance to glucocorticoids and/or at least one immunosuppressant. * The patient or their legal guardian provides written informed consent.
Exclusion criteria
* Female patients who are pregnant, breastfeeding, or planning a pregnancy during the trial period. * Patients with active infections, such as herpes zoster, HIV, active tuberculosis, active hepatitis, HBsAg-positive patients, or HCV antibody-positive patients. * Patients with positive test results indicating COVID-19 infection within 1 month prior to baseline. * Patients with a history of or currently diagnosed malignancy. * Patients with significant cardiovascular diseases (including severe arrhythmia), hepatic, renal, respiratory, endocrine, or hematological disorders, or any other medical condition that, in the investigator's judgment, would interfere with participation in the study or require hospitalization during the trial. * Patients who have received intravenous immunoglobulin (IVIG) or plasmapheresis within 1 month prior to baseline. * Patients who have received other targeted biologic therapies, such as rituximab, eculizumab, tocilizumab, etc., within 3 months prior to baseline. * Patients who have received any live vaccine within 3 months prior to baseline or plan to receive any vaccine during the study period. * Patients with a known allergy to human-derived biologics. * Patients currently participating in another clinical trial. * Patients deemed unsuitable for participation by the investigator for other reasons (e.g., severe psychiatric disorders).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physician's Global Assessment (PGA) Score | From enrollment to the end of treatment at 12 weeks |
Contacts
CONTACTZhaoyou Meng
Outcome results
None listed